1h Free Analyst Time
The publisher has been monitoring the phenylketonuria treatment market and it is poised to grow by $481.45 mn during 2022-2026, progressing at a CAGR of 9.06% during the forecast period. The report on the phenylketonuria treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rising investments in genomic research and development and the increasing prevalence of PKU.
The phenylketonuria treatment market analysis includes the drug segment and geographic landscape.
The phenylketonuria treatment market is segmented as below:
By Drug
- Sapropterin
- Pegvaliase-pqpz
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the strong pipeline of PKU drugs as one of the prime reasons driving the phenylketonuria treatment market growth during the next few years.
The report on phenylketonuria treatment market covers the following areas:
- Phenylketonuria treatment market sizing
- Phenylketonuria treatment market forecast
- Phenylketonuria treatment market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phenylketonuria treatment market vendors that include American Gene Technologies, BioMarin Pharmaceutical Inc., Codexis Inc., Evox Therapeutics Ltd., Homology Medicines Inc., Jnana Therapeutics, SOM INNOVATION BIOTECH SA, and Synlogic Inc. Also, the phenylketonuria treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2021
- Market outlook: Forecast for 2021 - 2026
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Drug
- Market segments
- Comparison by Drug
- Sapropterin - Market size and forecast 2021-2026
- Pegvaliase-pqpz - Market size and forecast 2021-2026
- Market opportunity by Drug
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2021-2026
- Europe - Market size and forecast 2021-2026
- Asia - Market size and forecast 2021-2026
- ROW - Market size and forecast 2021-2026
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- American Gene Technologies
- BioMarin Pharmaceutical Inc.
- Codexis Inc.
- Evox Therapeutics Ltd.
- Homology Medicines Inc.
- Jnana Therapeutics
- SOM INNOVATION BIOTECH SA
- Synlogic Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2021 - 2026 ($ million)
- Global market: Year-over-year growth 2021 - 2026 (%)
- Five forces analysis 2021 & 2026
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2021
- Drug - Market share 2021-2026 (%)
- Comparison by Drug
- Sapropterin - Market size and forecast 2021-2026 ($ million)
- Sapropterin - Year-over-year growth 2021-2026 (%)
- Pegvaliase-pqpz - Market size and forecast 2021-2026 ($ million)
- Pegvaliase-pqpz - Year-over-year growth 2021-2026 (%)
- Market opportunity by Drug
- Customer landscape
- Market share By Geographical Landscape 2021-2026 (%)
- Geographic comparison
- North America - Market size and forecast 2021-2026 ($ million)
- North America - Year-over-year growth 2021-2026 (%)
- Europe - Market size and forecast 2021-2026 ($ million)
- Europe - Year-over-year growth 2021-2026 (%)
- Asia - Market size and forecast 2021-2026 ($ million)
- Asia - Year-over-year growth 2021-2026 (%)
- ROW - Market size and forecast 2021-2026 ($ million)
- ROW - Year-over-year growth 2021-2026 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- American Gene Technologies - Overview
- American Gene Technologies - Product and service
- American Gene Technologies - Key offerings
- American Gene Technologies - Key customers
- American Gene Technologies - Segment focus
- BioMarin Pharmaceutical Inc. - Overview
- BioMarin Pharmaceutical Inc. - Product and service
- BioMarin Pharmaceutical Inc. - Key offerings
- BioMarin Pharmaceutical Inc. - Key customers
- BioMarin Pharmaceutical Inc. - Segment focus
- Codexis Inc. - Overview
- Codexis Inc. - Business segments
- Codexis Inc. - Key offerings
- Codexis Inc. - Key customers
- Codexis Inc. - Segment focus
- Evox Therapeutics Ltd. - Overview
- Evox Therapeutics Ltd. - Product and service
- Evox Therapeutics Ltd. - Key offerings
- Evox Therapeutics Ltd. - Key customers
- Evox Therapeutics Ltd. - Segment focus
- Homology Medicines Inc. - Overview
- Homology Medicines Inc. - Product and service
- Homology Medicines Inc. - Key offerings
- Homology Medicines Inc. - Key customers
- Homology Medicines Inc. - Segment focus
- Jnana Therapeutics - Overview
- Jnana Therapeutics - Product and service
- Jnana Therapeutics - Key offerings
- Jnana Therapeutics - Key customers
- Jnana Therapeutics - Segment focus
- SOM INNOVATION BIOTECH SA - Overview
- SOM INNOVATION BIOTECH SA - Product and service
- SOM INNOVATION BIOTECH SA - Key offerings
- SOM INNOVATION BIOTECH SA - Key customers
- SOM INNOVATION BIOTECH SA - Segment focus
- Synlogic Inc. - Overview
- Synlogic Inc. - Product and service
- Synlogic Inc. - Key offerings
- Synlogic Inc. - Key customers
- Synlogic Inc. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global phenylketonuria treatment market: American Gene Technologies, BioMarin Pharmaceutical Inc., Codexis Inc., Evox Therapeutics Ltd., Homology Medicines Inc., Jnana Therapeutics, SOM INNOVATION BIOTECH SA, and Synlogic Inc.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is strong pipeline of PKU drugs."
According to the report, one of the major drivers for this market is the rising investments in genomic research and development.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- American Gene Technologies
- BioMarin Pharmaceutical Inc.
- Codexis Inc.
- Evox Therapeutics Ltd.
- Homology Medicines Inc.
- Jnana Therapeutics
- SOM INNOVATION BIOTECH SA
- Synlogic Inc.
